Jun-Pyo Choi

Jun-Pyo Choi

Auto-generated profile, based on publicly available information

Jun-Pyo Choi

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
PLPurevsuren Losol
Purevsuren Losol
MSMilena Sokolowska
Milena Sokolowska
YHYU KYOUNG HWANG
YU KYOUNG HWANG
IOIsmail Ogulur
Ismail Ogulur
YMYasutaka Mitamura
Yasutaka Mitamura
CACezmi A. Akdis
Cezmi A. Akdis
Losol P, et al. Allergy Asthma Immunol Res. 2023 Nov;15(6):705-724. https://doi.org/10.4168/aair.2023.15.6.705

1 January 2021 in Immune Network
Verified
Journal Article
Open access
PDF file
PLPurevsuren Losol
Purevsuren Losol
JCJun-Pyo Choi
Jun-Pyo Choi
SKSae-Hoon Kim
Sae-Hoon Kim
YCYoon-Seok Chang
Yoon-Seok Chang
Losol P, et al. Immune Netw. 2021 Jun;21(3):e19. https://doi.org/10.4110/in.2021.21.e19

13 March 2023 in Allergy
Verified
Journal Article
Closed access
BGBon‐Hee Gu
Bon‐Hee Gu
JCJun‐Pyo Choi
Jun‐Pyo Choi
TPTansol Park
Tansol Park
AKA‐Sol Kim
A‐Sol Kim
HJHo Young Jung
Ho Young Jung
HPHan-Ki Park
Han-Ki Park

31 October 2022 in Asia Pacific Allergy
Verified
Journal Article
Open access
PDF file
JLJuan-Felipe López
Juan-Felipe López
MIManal Bel Imam
Manal Bel Imam
PSPattraporn Satitsuksanoa
Pattraporn Satitsuksanoa
SLSophieke Lems
Sophieke Lems
MYMinglin Yang
Minglin Yang
WVWillem van de Veen
Willem van de Veen
Allergen-specific immunotherapy (AIT) is considered the only curative treatment for allergic diseases mediated by immunoglobulin E (IgE). Currently, the route of administration depends both on the different types of causal allergens and on its effectiveness and safety profile. Several studies have reported the mechanisms and changes in humoral and cellular response underlying AIT; however, the full picture remains unknown. Knowledge of who can benefit from this type of treatment is urgently needed due to the patient safety risks and costs of AIT. In vivo or in vitro biomarkers have become a strategy to predict clinical outcomes in precision medicine. There are currently no standardized biomarkers that allow determining successful responses to AIT, however, some studies have found differences between responders and nonresponders. In addition, different candidates have been postulated that may have the potential to become biomarkers. In this review, we aim to summarize the findings to date related to biomarkers in different IgE-mediated allergic diseases (respiratory, food, and venom allergy) with the potential to define who will benefit from AIT.

22 November 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
JCJun‐Pyo Choi
Jun‐Pyo Choi
SPSo Young Park
So Young Park
KMKeun‐Ai Moon
Keun‐Ai Moon
EHEun Hee Ha
Eun Hee Ha
YWYeon Duk Woo
Yeon Duk Woo
YCYou Sook Cho
You Sook Cho

12 October 2018 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
JCJun‐Pyo Choi
Jun‐Pyo Choi
SJSeong Gyu Jeon
Seong Gyu Jeon
YKYoon‐Keun Kim
Yoon‐Keun Kim
YCYou Sook Cho
You Sook Cho